Capstone Therapeutics Corp. (CAPS)
USD 3.0
(-11.76%)
USD 3.0
(-11.76%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 20.32 Million USD | -29.43% |
| 2022 | 28.8 Million USD | 1.64% |
| 2021 | 28.34 Million USD | 36.2% |
| 2020 | 20.8 Million USD | 668.11% |
| 2019 | 2.7 Million USD | 19.76% |
| 2018 | 2.26 Million USD | 0.58% |
| 2017 | 2.24 Million USD | 124.9% |
| 2016 | 1 Million USD | 0.0% |
| 2015 | 1 Million USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 21.33 Million USD | -1.16% |
| 2024 Q1 | 21.58 Million USD | 6.19% |
| 2023 Q3 | 28.95 Million USD | -2.9% |
| 2023 FY | 20.32 Million USD | -29.43% |
| 2023 Q1 | 31.15 Million USD | 8.14% |
| 2023 Q2 | 29.81 Million USD | -4.29% |
| 2023 Q4 | 20.32 Million USD | -29.78% |
| 2022 Q4 | 28.8 Million USD | -8.71% |
| 2022 Q3 | 31.55 Million USD | 9.89% |
| 2022 FY | 28.8 Million USD | 1.64% |
| 2022 Q1 | 31.31 Million USD | 10.48% |
| 2022 Q2 | 28.71 Million USD | -8.3% |
| 2021 Q3 | 27.77 Million USD | -3.24% |
| 2021 Q4 | 28.34 Million USD | 2.02% |
| 2021 Q1 | 31.18 Million USD | 49.86% |
| 2021 FY | 28.34 Million USD | 36.2% |
| 2021 Q2 | 28.7 Million USD | -7.93% |
| 2020 Q4 | 20.8 Million USD | 55.87% |
| 2020 FY | 20.8 Million USD | 668.11% |
| 2020 Q3 | 13.35 Million USD | 0.0% |
| 2019 Q3 | 3.07 Million USD | 16.15% |
| 2019 Q4 | 3.07 Million USD | 0.0% |
| 2019 FY | 2.7 Million USD | 19.76% |
| 2019 Q1 | 2.58 Million USD | 4.4% |
| 2019 Q2 | 2.64 Million USD | 2.32% |
| 2018 FY | 2.26 Million USD | 0.58% |
| 2018 Q4 | 2.47 Million USD | 2.48% |
| 2018 Q3 | 2.41 Million USD | 2.55% |
| 2018 Q2 | 2.35 Million USD | 2.57% |
| 2018 Q1 | 2.29 Million USD | 2.09% |
| 2017 FY | 2.24 Million USD | 124.9% |
| 2017 Q1 | 1 Million USD | 0.0% |
| 2017 Q2 | 1 Million USD | 0.0% |
| 2017 Q3 | 2.15 Million USD | 115.9% |
| 2017 Q4 | 2.24 Million USD | 4.17% |
| 2016 FY | 1 Million USD | 0.0% |
| 2016 Q4 | 1 Million USD | 0.0% |
| 2016 Q3 | 1 Million USD | 0.0% |
| 2016 Q2 | 1 Million USD | 0.0% |
| 2016 Q1 | 1 Million USD | 0.0% |
| 2015 FY | 1 Million USD | 0.0% |
| 2015 Q4 | 1 Million USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 50.664% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -393.164% |
| SQZ Biotechnologies Company | 27.47 Million USD | 26.002% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 53.132% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 31.71% |
| Mesoblast Limited | 118.7 Million USD | 82.875% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -2043.691% |
| Genus plc | 233.1 Million USD | 91.279% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -593.697% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -1412.968% |
| Marizyme, Inc. | 18.71 Million USD | -8.604% |
| ContraFect Corporation | 2.88 Million USD | -605.588% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -2610.4% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -14903.653% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -1305.499% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -773.964% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -259.256% |
| MultiCell Technologies, Inc. | 202.58 USD | -10034454.25% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 64.64% |
| EV Biologics, Inc. | 1.49 Million USD | -1259.959% |
| Q BioMed Inc. | 4.1 Million USD | -394.601% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 38.588% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -3126.272% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -1554.888% |
| Biomind Labs Inc. | 735.54 Thousand USD | -2663.676% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 88.15% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | -56.405% |
| Skye Bioscience, Inc. | 4.61 Million USD | -340.451% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -2189.024% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -14264.25% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -246.239% |
| IMV Inc. | 28.88 Million USD | 29.622% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -78938.843% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -800.114% |
| GB Sciences, Inc. | 1.75 Million USD | -1055.455% |
| Alpha Cognition Inc. | 1.22 Million USD | -1565.722% |
| HST Global, Inc. | 98.31 Thousand USD | -20575.556% |
| CSL Limited | 12.18 Billion USD | 99.833% |
| Halberd Corporation | 150 Thousand USD | -13452.0% |
| Enzolytics Inc. | 996.33 Thousand USD | -1940.271% |
| Resverlogix Corp. | 6.49 Million USD | -213.172% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -4157.173% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -7853.301% |
| argenx SE | 20 Million USD | -1.64% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 55.382% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -650.47% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -198706.846% |
| Genscript Biotech Corporation | 417.73 Million USD | 95.134% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -10032.791% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -747.804% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -8765.59% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 69.948% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -571.736% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -5551.219% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -13574.708% |
| BioStem Technologies, Inc. | 4.71 Million USD | -331.463% |
| ONE Bio Corp. | 19.71 Million USD | -3.109% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -8025.285% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -8073.046% |
| Agentix Corp. | 50 Thousand USD | -40556.0% |
| LadRx Corporation | 33.6 Thousand USD | -60389.198% |
| Cell Source, Inc. | 9.25 Million USD | -119.663% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -2588.164% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -2588.164% |
| NovAccess Global Inc. | 2.19 Million USD | -824.05% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -187.411% |
| Itoco Inc. | 228.37 Thousand USD | -8801.071% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -9535.265% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -307.947% |
| Kadimastem Ltd | 891.22 Thousand USD | -2180.903% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -4958.617% |
| CytoDyn Inc. | 30.07 Million USD | 32.411% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -4097.537% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -5677.511% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -159.95% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -16494.286% |
| Rebus Holdings, Inc. | 310 Thousand USD | -6457.419% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -329.288% |
| International Stem Cell Corporation | 4.17 Million USD | -386.549% |
| Bioxytran, Inc. | 1.92 Million USD | -956.0% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -32470.138% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -832.092% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -144.444% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -136.785% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -1206.864% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -7485.075% |
| Neutra Corp. | 54.15 Thousand USD | -37436.007% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -1010.82% |
| PureTech Health plc | 25.51 Million USD | 20.32% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -1560.478% |
| IXICO plc | 472.02 Thousand USD | -4206.57% |
| IntelGenx Technologies Corp. | 15.5 Million USD | -31.14% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 67.351% |
| CSL Limited | 12.18 Billion USD | 99.833% |
| Cellectis S.A. | 92.77 Million USD | 78.089% |